Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IWWM-12 2024 | Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström’s macroglobulinemia

Naohiro Sekiguchi • 18 Oct 2024
IWWM-12 2024
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Antibodies BTK inhibitors Ibrutinib Rituximab Tirabrutinib
iNNOVATE

Naohiro Sekiguchi, MD, PhD, National Hospital Organization Disaster Medical Center, Tachikawa, Japan, discusses a study investigating ibrutinib plus rituximab in symptomatic patients with Waldenström’s macroglobulinemia in Japan. Positive findings from this study supported the approval of this combination in Japan. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria: Janssen, Ono; Research funding: Incyte Biosciences Japan, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, Ono.

More from Naohiro Sekiguchi

Hyperviscosity syndrome as a complication in WM and its management with plasma exchange
1:04
Hyperviscosity syndrome as a complication in WM and its management with plasma exchange
Naohiro Sekiguchi • 18 Oct 2024
Tirabrutinib, a second-generation BTKi, in the treatment of symptomatic WM and Bing-Neel syndrome
2:01
Tirabrutinib, a second-generation BTKi, in the treatment of symptomatic WM and Bing-Neel syndrome
Naohiro Sekiguchi • 18 Oct 2024

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals